| 2017-03 |
Cuore Inc. (now Qualips Co., Ltd.): Established in Yokohama, Kanagawa Prefecture |
| 2017-03-21 |
Date of establishment: March 21, 2017. |
| 2017-03-21 |
The established CellCube Co., Ltd. founded and established Cuore Co., Ltd. (our company) in Nishi-ku, Yokohama City, Kanagawa Prefecture, for the commercialization of human iPS cell-derived cardiomyocyte sheets. |
| 2017-06 |
Received a business transfer from CellCube Inc. and inherited the joint research course "Advanced Regenerative Medicine Joint Research Course" in collaboration with Osaka University |
| 2017-06 |
Changed company name to Qualips Co., Ltd. |
| 2017-06 |
Received a business transfer of human iPS cell-derived cardiomyocyte sheets from CellCube Co., Ltd., and succeeded the joint research course 'Advanced Regenerative Medicine Joint Research Course' in collaboration with Osaka University (ending at the end of September 2025). |
| 2017-08 |
Signed a stock underwriting agreement with Daiichi Sankyo Co., Ltd. |
| 2017-09 |
Changed the company name from Cuore Co., Ltd. to Qualips Co., Ltd. |
| 2017-10 |
Signed a joint research and development agreement with Daiichi Sankyo Co., Ltd. |
| 2017-12 |
Established Qualips Healthcare Science Co., Ltd. as a consolidated subsidiary in Chuo-ku, Tokyo. |
| 2017-12 |
Established iReheart Inc. as a consolidated subsidiary in the United States. |
| 2017-12 |
Signed a joint research contract with Stanford University Cardiac and Thoracic Surgery in the United States. |
| 2018-02 |
Established a research facility (joint research course) within Osaka University, Suita Campus |
| 2018-03 |
Submitted a clinical research trial plan on ischemic heart disease using human iPS cell-derived cardiomyocyte sheets at Osaka University |
| 2018-06 |
Moved headquarters to Chuo-ku, Tokyo |
| 2018-07 |
Implemented a third-party allotment of shares with Daiichi Sankyo Co., Ltd., Kyoto University Innovation Capital Co., Ltd., and others as underwriters |
| 2019-10 |
Osaka University submitted a clinical trial application for a physician-led trial on ischemic heart disease using human iPS cell-derived cardiomyocyte sheets to the Pharmaceuticals and Medical Devices Agency (PMDA); our company supported the trial |
| 2020-01 |
Commenced the physician-led trial (Cohort A) with the first transplant |
| 2020-03 |
Commenced construction of a commercial cell culture and processing facility (codenamed "CLiC-1") that also serves as our research facility in Minoh City, Osaka Prefecture |
| 2020-11 |
Completed the physician-led trial (Cohort A) with the third transplant |
| 2020-12 |
Implemented a third-party allotment of shares with Daikou Pharmaceutical Co., Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Co., Ltd., Daidan Co., Ltd., Stem Cell Research Institute Co., Ltd., Asahi Intech Co., Ltd. (headquarters: Seto City, Aichi Prefecture), and others as underwriters |
| 2021-03 |
Implemented a third-party allotment of shares with JIC Venture Growth Investments Co., Ltd. (operating JIC Venture Growth Fund No.1 LP), Jafco Group Co., Ltd. (operating Jafco SV6 LP), Jafco SV6-S LP, Japan Venture Capital Co., Ltd. (operating Kyoto University Venture NVCC No.2 LP), Osaka University Venture NVCC No.1 LP, Fujifilm Co., Ltd., CellSource Co., Ltd., and others as underwriters |
| 2021-08 |
Appointed Professor Yoshiki Sawazaki (Special Appointment) from the Department of Health Sciences, Graduate School of Medicine, Osaka University, as Chief Technology Officer (CTO) |
| 2021-09 |
Commercial cell culture processing facility (codenamed 'CLiC-1') obtained a 'Special Cell Processing Product Manufacturing Permit' (facility number: FA5210001). |
| 2021-10 |
Agreed to a contract with VC Cell Therapy Co., Ltd. regarding the manufacturing and quality control of investigational regenerative medicine products. |
| 2022-04 |
Signed a contract with Canon Cure Co., Ltd. concerning technical support and related matters. |
| 2022-04 |
Signed a joint research agreement with Asahi Intech Co., Ltd. for developing new regenerative medicine therapies. |
| 2022-08 |
The physician-led trial (Cohort B) commenced, and a transplant surgery was performed at Juntendo University Hospital (the first transplant). |
| 2022-09 |
Cell Source Co., Ltd. adopted our contract manufacturing services for specialized cell processing products. |
| 2023-03 |
The physician-led trial (Cohort B) concluded (the fifth transplant completed). |
| 2023-06 |
Listed on the Tokyo Stock Exchange Growth Market. |
| 2023-11 |
Decided to occupy a business base in Silicon Valley (established by the Ministry of Economy, Trade and Industry). |
| 2023-12 |
Established Qualips Healthcare Science Co., Ltd. to conduct cultured supernatant business in Chuo-ku, Tokyo. |
| 2026-03 |
Signed a joint research and development contract with Daiichi Sankyo Co., Ltd. to obtain manufacturing and sales approval for human iPS cell-derived cardiomyocyte sheets (ending at the end of March 2026). |
